These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1311892)

  • 21. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity.
    Ghigo E; Procopio M; Boffano GM; Arvat E; Valente F; Maccario M; Mazza E; Camanni F
    Metabolism; 1992 May; 41(5):560-3. PubMed ID: 1588839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for somatomedin-C mediated inhibition.
    Loche S; Cappa M; Borrelli P; Faedda A; Crinò A; Cella SG; Corda R; Müller EE; Pintor C
    Clin Endocrinol (Oxf); 1987 Aug; 27(2):145-53. PubMed ID: 3117449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blunted growth hormone (GH) responsiveness to GH-releasing hormone in obese patients: influence of prolonged administration of the serotoninergic drug fenfluramine.
    Argenio GF; Bernini GP; Sgró M; Vivaldi MS; Del Corso C; Santoni R; Franchi F
    Metabolism; 1991 Jul; 40(7):724-7. PubMed ID: 1870427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
    Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
    Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective beta 1-adrenergic receptor-blockade with atenolol enhances growth hormone releasing hormone and mediated growth hormone release in man.
    Mauras N; Blizzard RM; Thorner MO; Rogol AD
    Metabolism; 1987 Apr; 36(4):369-72. PubMed ID: 2882405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atenolol enhances growth hormone release to exogenous growth hormone-releasing hormone but fails to alter spontaneous nocturnal growth hormone secretion in boys with constitutional delay of growth.
    Martha PM; Blizzard RM; Rogol AD
    Pediatr Res; 1988 Apr; 23(4):393-7. PubMed ID: 3131726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute hyperglycemia and activation of the beta-adrenergic system exhibit synergistic inhibitory actions on growth hormone (GH) releasing hormone-induced GH release.
    Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Park S
    Eur J Endocrinol; 2003 Jun; 148(6):635-40. PubMed ID: 12773135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatostatin pretreatment enhances growth hormone (GH) responsiveness to GH-releasing hormone: a potential new diagnostic approach to GH deficiency.
    Tzanela M; Guyda H; Van Vliet G; Tannenbaum GS
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2487-94. PubMed ID: 8675565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of propranolol on growth hormone response to GH releasing hormone (GHRH 1-44) in the dog.
    Regnier A; Bret L; Morre M
    Res Vet Sci; 1992 Jan; 52(1):110-2. PubMed ID: 1553429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion.
    Mota A; Bento A; Peñalva A; Pombo M; Dieguez C
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1973-7. PubMed ID: 7775648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
    Loche S; Cambiaso P; Carta D; Setzu S; Imbimbo BP; Borrelli P; Pintor C; Cappa M
    J Clin Endocrinol Metab; 1995 Feb; 80(2):674-8. PubMed ID: 7852535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dependent inhibition of growth hormone (GH)-releasing hormone-induced GH release by corticotropin-releasing hormone in prepubertal children.
    Ghizzoni L; Vottero A; Street ME; Bernasconi S
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1397-400. PubMed ID: 8636340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of feeding on the ultradian variation of the growth hormone (GH) response to GH-releasing hormone in normal subjects and patients with obesity and anorexia nervosa.
    De Marinis L; Folli G; D'Amico C; Mancini A; Sambo P; Tofani A; Oradei A; Barbarino A
    J Clin Endocrinol Metab; 1988 Mar; 66(3):598-604. PubMed ID: 3127419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormone.
    Ramos-Dias JC; Yateman M; Camacho-Hübner C; Grossman A; Lengyel AM
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):583-9. PubMed ID: 8548943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
    Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
    Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE
    J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.